Abstract
Background In this study we phenotyped individuals hospitalised with coronavirus disease 2019 (COVID-19) in depth, summarising entire medical histories, including medications, as captured in routinely collected data drawn from databases across three continents. We then compared individuals hospitalised with COVID-19 to those previously hospitalised with influenza.
Methods We report demographics, previously recorded conditions and medication use of patients hospitalised with COVID-19 in the US (Columbia University Irving Medical Center [CUIMC], Premier Healthcare Database [PHD], UCHealth System Health Data Compass Database [UC HDC], and the Department of Veterans Affairs [VA OMOP]), in South Korea (Health Insurance Review & Assessment [HIRA]), and Spain (The Information System for Research in Primary Care [SIDIAP] and HM Hospitales [HM]). These patients were then compared with patients hospitalised with influenza in 2014-19.
Results 34,128 (US: 8,362, South Korea: 7,341, Spain: 18,425) individuals hospitalised with COVID-19 were included. Between 4,811 (HM) and 11,643 (CUIMC) unique aggregate characteristics were extracted per patient, with all summarised in an accompanying interactive website (http://evidence.ohdsi.org/Covid19CharacterizationHospitalization/). Patients were majority male in the US (CUIMC: 52%, PHD: 52%, UC HDC: 54%, VA OMOP: 94%,) and Spain (SIDIAP: 54%, HM: 60%), but were predominantly female in South Korea (HIRA: 60%). Age profiles varied across data sources. Prevalence of asthma ranged from 4% to 15%, diabetes from 13% to 43%, and hypertensive disorder from 24% to 70% across data sources. Between 14% and 33% were taking drugs acting on the renin-angiotensin system in the 30 days prior to hospitalisation. Compared to 81,596 individuals hospitalised with influenza in 2014-19, patients admitted with COVID-19 were more typically male, younger, and healthier, with fewer comorbidities and lower medication use.
Conclusions We provide a detailed characterisation of patients hospitalised with COVID-19. Protecting groups known to be vulnerable to influenza is a useful starting point to minimize the number of hospital admissions needed for COVID-19. However, such strategies will also likely need to be broadened so as to reflect the particular characteristics of individuals hospitalised with COVID-19.
Competing Interest Statement
All authors have completed the ICMJE uniform disclosure form, with the following declarations made: DPA reports grants and other from AMGEN, grants, non-financial support and other from UCB Biopharma, grants from Les Laboratoires Servier, outside the submitted work; and Janssen, on behalf of IMI-funded EHDEN and EMIF consortiums, and Synapse Management Partners have supported training programmes organised by DPA's department and open for external participants. DV reports personal fees from Bayer, outside the submitted work; and he is a full-time employee at a pharmaceutical company. DM reports funding support from the Wellcome Trust, NIHR, Scottish CSO and Tenovus Scotland for research unrelated to this work. SCY reports grants from Korean Ministry of Health & Welfare, grants from Korean Ministry of Trade, Industry & Energy, during the conduct of the study. AG reports personal fees from Regeneron Pharmaceuticals, outside the submitted work; and she a full-time employee at Regeneron Pharmaceuticals. This work was not conducted at Regeneron Pharmaceuticals. YJ reports employee of AbbVie and own company stock. AA reports: I am currently employed at Alberta Health Services (AHS) as a Data Science Lead redeployed as an epidemiologist to aid in the COVID-19 response. This work was not conducted at AHS, within AHS working hours, or with AHS staff. I contributed and conducted this work as an Independent Epidemiologist, as a member of the Observational Health Data Sciences and Informatics (OHDSI) Network. PR reports grants from Innovative Medicines Initiative, grants from Janssen Research and Development, during the conduct of the study. MS reports grants from US National Science Foundation, grants from US National Institutes of Health, grants from IQVIA, personal fees from Janssen Research and Development, during the conduct of the study. GH reports grants from US NIH National Library of Medicine, during the conduct of the study; grants from Janssen Research, outside the submitted work. APU reports grants from Fundacion Alfonso Martin Escudero, grants from Medical Research Council, outside the submitted work. HA reports personal fees from Eli Lilly and Company, outside the submitted work. AS reports personal fees from Janssen Research & Development, during the conduct of the study; personal fees from Janssen Research & Development, outside the submitted work. AS is a full time employee of Janssen and shareholder of Johnson & Johnson. GR is a full time employee of Janssen and shareholder of Johnson & Johnson. FD reports personal fees from Janssen Research & Development, during the conduct of the study; personal fees from Janssen Research & Development, outside the submitted work. RWP reports grants from Korean Ministry of Health & Welfare, grants from Korean Ministry of Trade, Industry & Energy, during the conduct of the study. JP reports grants from Korean Ministry of Health & Welfare, grants from Korean Ministry of Trade, Industry & Energy, during the conduct of the study. JC reports grants from Korean Ministry of Health & Welfare, grants from Korean Ministry of Trade, Industry & Energy, during the conduct of the study. SD reports grants from Anolinx, LLC, grants from Astellas Pharma, Inc, grants from AstraZeneca Pharmaceuticals LP, grants from Boehringer Ingelheim International GmbH, grants from Celgene Corporation, grants from Eli Lilly and Company, grants from Genentech Inc.,, grants from Genomic Health, Inc., grants from Gilead Sciences Inc., grants from GlaxoSmithKline PLC, grants from Innocrin Pharmaceuticals Inc., grants from Janssen Pharmaceuticals, Inc., grants from Kantar Health, grants from Myriad Genetic Laboratories, Inc., grants from Novartis International AG, grants from Parexel International Corporation through the University of Utah or Western Institute for Biomedical Research outside the submitted work. HJ reports grants from Korean Ministry of Health & Welfare, grants from Korean Ministry of Trade, Industry & Energy, during the conduct of the study. BSKH reports grants from Innovation Fund Denmark (5153-00002B) and the Novo Nordisk Foundation (NNF14CC0001), outside the submitted work. KK reports she is an employee of IQVIA. CR reports he is an employee of IQVIA. JS reports other from Janssen R&D, during the conduct of the study; other from Janssen R&D, outside the submitted work; and JS was a full-time employee of Johnson & Johnson, or a subsidiary, at the time the study was conducted. JS owns stock, stock options, and pension rights from the company. RM reports and is employee of Janssen Research and Development. WG is an AbbVie employee. PR reports and is employee of Janssen Research and Development and shareholder of Johnson & Johnson. MS is a full-time employee of Janssen R&D, and a shareholder of Johnson & Johnson. JH reports other from Janssen Research & Development, during the conduct of the study; other from Janssen Research & Development, outside the submitted work; and full time employee of Janssen and shareholder of Johnson & Johnson.
Funding Statement
This project has received support from the European Health Data and Evidence Network (EHDEN) project. EHDEN has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 806968. The JU receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA. This research received partial support from the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC), US National Institutes of Health, US Department of Veterans Affairs, Janssen Research & Development, and IQVIA. This work was also supported by the Bio Industrial Strategic Technology Development Program (20001234) funded by the Ministry of Trade, Industry & Energy (MOTIE, Korea) and a grant from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea [grant number: HI16C0992]. Personal funding included Versus Arthritis [21605], Medical Research Council Doctoral Training Partnership (MRC-DTP) [MR/K501256/1] (JL); Medical Research Council (MRC) and Fundación Alfonso Martín Escudero (FAME) (APU); Innovation Fund Denmark (5153-00002B) and the Novo Nordisk Foundation (NNF14CC0001) (BSKH); VINCI [VA HSR RES 13-457] (SLD, MEM, KEL); NIHR Senior Research Fellowship (SRF-2018-11-ST2-004, DPA); Bill & Melinda Gates Foundation (INV-016201); the Intramural Research Program of the National Institutes of Health / National Library of Medicine / Lister Hill National Center for Biomedical Communications (VH); and the Direcció General de Recerca i Innovació en Salut from the Department of Health of the Generalitat de Catalunya. No funders had a direct role in this study. The views and opinions expressed are those of the authors and do not necessarily reflect those of the Clinician Scientist Award programme, NIHR, Department of Veterans Affairs or the United States Government, NHS or the Department of Health, England.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All the data partners received Institutional Review Board (IRB) approval or exemption. STARR-OMOP had approval from IRB Panel #8 (RB-53248) registered to Leland Stanford Junior University under the Stanford Human Research Protection Program (HRPP). The use of VA data was reviewed by the Department of Veterans Affairs Central Institutional Review Board (IRB) and was determined to meet the criteria for exemption under Exemption Category 4(3) and approved the request for Waiver of HIPAA Authorization. The research was approved by the Columbia University Institutional Review Board as an OHDSI network study. The IRB number for use of HIRA data was AJIB-MED-EXP-20-065. HM Hospitales and SIDIAP analyses were approved by the Clinical Research Ethics Committee of the IDIAPJGol (project code: 20/070-PCV). The UC-HDC data use was reviewed by Colorado Multi-Institutional Review Board (COMIRB) and was determined to meet the criteria for exemption under Exemption Category 4(3) and approved the request for Waiver of HIPAA Authorization (protocol # 20-0730).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Open Science is a guiding principle within OHDSI. As such, we provide unfettered access to all open-source analysis tools employed in this study via https://github.com/OHDSI/, as well as all data and results artefacts that do not include patient-level health information via http://evidence.ohdsi.org/Covid19CharacterizationHospitalization/. Data partners contributing to this study remain custodians of their individual patient-level health information and hold either IRB exemption or approval for participation.
http://evidence.ohdsi.org/Covid19CharacterizationHospitalization/
